UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of Registrant as Specified in Its Charter)
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s Telephone Number, Including Area Code:
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
Name of each exchange | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 10, 2025, Adaptive Biotechnologies Corporation (the “Company”) held its annual meeting of shareholders (the “Annual Meeting”) pursuant to notice duly given. Three proposals were presented for voting: Proposal 1: election of the Class III director to the Board of Directors (Chad Robins); Proposal 2: an advisory request concerning compensation for the Company’s 2024 named executive officers; and, Proposal 3: ratification of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2025. Each of the proposals was described in detail in the Company’s definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 29, 2025. A quorum of the shareholders voted by the conclusion of the Annual Meeting. The final results of the voting are set forth below.
Proposal 1: Election of Class III Director
| Chad Robins |
Votes Submitted | As % of Proposal Votes | Broker Non Vote | |||||||||
| For |
103,695,675 | 80.95 | % | 12,805,961 | ||||||||
| Against |
819 | — | ||||||||||
| Withhold/Abstain |
24,409,068 | 19.05 | % | |||||||||
Proposal 2: Advisory Vote Concerning the 2024 Compensation of the Company’s Named Executive Officers
| Votes Submitted | As % of Proposal Votes | Broker Non Vote | ||||||||||
| For |
126,126,999 | 98.46 | % | 12,805,961 | ||||||||
| Against |
1,580,695 | 1.23 | % | |||||||||
| Withhold/Abstain |
397,868 | 0.31 | % | |||||||||
Proposal 3: Ratification of Ernst & Young LLP as the Company’s Independent Registered Public Accounting Firm for the Year Ending December 31, 2025
| Votes Submitted | As % of Proposal Votes | Broker Non Vote | ||||||||||
| For |
140,778,854 | 99.91 | % | 0 | ||||||||
| Against |
113,955 | 0.08 | % | |||||||||
| Withhold/Abstain |
18,714 | 0.01 | % | |||||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Adaptive Biotechnologies Corporation | ||||||
| Date: June 12, 2025 | By: | /s/ Kyle Piskel | ||||
| Kyle Piskel Chief Financial Officer | ||||||